Mycotoxin Treatments Summit 2016

Evaluation Process for Buildings and Individuals with Suspected Mold Exposure

Alfred Johnson, D.O.

Depression & Mycotoxicosis in a Female College Student

Richard G. Jaeckle, M.D., F.A.P.A., F.A.A.C.A.P., F.A.A.E.M., F.A.A.O.A.

Treatment Approach for Chronic Mold and Mycotoxin Illness

Joseph Brewer, M.D.

Evaluation and Treatment of Pulmonary Disease Developed After Exposure to Indoor Mold Contamination – A Case Study

Adrienne Sprouse, M.D., M.ED.

Toxic Exposure To Molds And Mycotoxins In Building Related Illness

William Rea, M.D.

The Secret Cause Of Disease

Gordon J. Crozier, D.O.

Gliotoxin Presence in Patients

Joseph Brewer, M.D.

The rationale for the Use of Liposomal Glutathione in the Management of Mycotoxin-Related Conditions

Frederick T. Guilford, M.D.

Diagnosing Mycotoxin Related Illness and Treatment Plans Incorporating Genetic Detoxification and Methylation Pathways

Ann Shippy, M.D.

Remediation of Mold Contaminated Structures and Treatment of the Mold Injured Individual

Alfred Johnson, D.O.

Mycotoxins and Depletion of Glutathione

Dr. Fredrick Guilford

Mycotoxin Treatments Summit 2013

Sick Building Syndrome

David Strauss, Ph.D.

Mycotoxins: Structure, Function, and Testing Procedures

Dennis Hooper, MD, Ph.D.

Aspects of Toxin Production, Exposure and Health

Harriet Ammann, Ph.D., D.D.B.T.


ELISA vs. Mass Spectrometery